AngioDynamics (NASDAQ:ANGO) Issues FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.340–0.310 for the period, compared to the consensus estimate of -0.370. The company issued revenue guidance of $285.0 million-$288.0 million, compared to the consensus revenue estimate of $284.9 million. AngioDynamics also updated its FY25 guidance to ($0.34)-($0.31) EPS.

AngioDynamics Stock Up 2.9 %

AngioDynamics stock opened at $9.66 on Wednesday. The firm has a market capitalization of $390.90 million, a P/E ratio of -1.72 and a beta of 0.56. The firm has a fifty day moving average of $10.30 and a 200-day moving average of $8.84. AngioDynamics has a 52-week low of $5.47 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm’s revenue was down .1% compared to the same quarter last year. During the same period last year, the company posted ($0.05) earnings per share. On average, research analysts expect that AngioDynamics will post -0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright upped their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is owned by insiders.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.